VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum

August 25, 2026 - VivoSim Labs, Inc. (NASDAQ: VIVS) is drawing investor attention following an initiation-of-coverage research report highlighting the company's NAMkind Trademark 3D human tissue models, AI-powered toxicology analytics, early commercial traction and potential opportunity from accelerating adoption of New Approach Methodologies (NAMs).

The report describes VivoSim as positioned at the intersection of 3D human biology, artificial intelligence, predictive toxicology and preclinical drug development, with technology designed to help pharmaceutical companies identify potential safety problems earlier and reduce reliance on conventional animal testing.

Predictive 3D Toxicology Meets AI

According to the report, VivoSim's NAMkind Trademark Liver platform demonstrated approximately 91% predictive accuracy, 90% sensitivity and 95% specificity against clinical drug-induced liver injury outcomes across a 92-compound dataset. Its VitroSense Trademark AI platform separately reported up to 96% accuracy predicting drug-induced diarrhea using data from the company's human intestinal models.

The platform is designed for higher-throughput pharmaceutical screening, potentially allowing drug developers to identify toxicity liabilities earlier in the development process.

FDA Momentum and ADC Opportunity

The report highlights growing FDA support for New Approach Methodologies and human-relevant alternatives to animal testing as a potential regulatory tailwind for VivoSim.

The company is also targeting antibody-drug conjugate (ADC) development, where its liver and intestinal models could help pharmaceutical companies evaluate payload, linker and other toxicity risks earlier.

Commercial Expansion Underway

VivoSim has begun moving from scientific validation toward commercialization, establishing APAC distribution relationships in China and Korea and announcing its first commercial NAMkind sales in China.

The company also recently received a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) related to a previously divested drug program. Management has separately guided for 500%+ revenue growth in fiscal 2027, driven by anticipated expansion of its NAM-based contract research services.

For investors following VIVS stock, AI biotech, FDA animal-testing alternatives, 3D human tissue models, predictive toxicology, ADC drug development and New Approach Methodologies, the report positions VivoSim as an emerging company to watch as pharmaceutical research moves toward more predictive, human-relevant testing. [https://thestreetreports.com/wp-content/uploads/2026/08/VIVS-Report.pdf]

Alongside VivoSim Labs, Inc. (NASDAQ: VIVS), investors are also watching several actively traded stocks under $1, including CID HoldCo Inc (NASDAQ: DAIC), Planet Green Corp (NYSE: PLAG), IGC Pharma (NYSE: IGC) and NexGel Inc (NASDAQ: NXGL) as small-cap, micro-cap and nano-cap stocks continue to attract trading interest.

About VivoSim Labs

VivoSim Labs, Inc. (NASDAQ: VIVS) provides pharmaceutical and biotechnology companies with 3D human liver and intestinal tissue models for drug testing and toxicology using New Approach Methodologies (NAMs). Its technology is designed to support more human-relevant preclinical drug-safety and development decisions.

About The Street Reports

The Street Reports (TSR) is a financial media and reader awareness platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=vivosim-labs-nasdaq-vivs-research-report-highlights-aipowered-drug-toxicity-platform-fda-nam-momentum]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.